HRP20150643T1 - Oralno primjenjive farmaceutske pelete s epidermalnim faktorom rasta - Google Patents
Oralno primjenjive farmaceutske pelete s epidermalnim faktorom rasta Download PDFInfo
- Publication number
- HRP20150643T1 HRP20150643T1 HRP20150643TT HRP20150643T HRP20150643T1 HR P20150643 T1 HRP20150643 T1 HR P20150643T1 HR P20150643T T HRP20150643T T HR P20150643TT HR P20150643 T HRP20150643 T HR P20150643T HR P20150643 T1 HRP20150643 T1 HR P20150643T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- pellets
- core
- pellets according
- growth factor
- Prior art date
Links
- 239000008188 pellet Substances 0.000 title claims 22
- 102000009024 Epidermal Growth Factor Human genes 0.000 title claims 7
- 101800003838 Epidermal growth factor Proteins 0.000 title claims 7
- 229940116977 epidermal growth factor Drugs 0.000 title claims 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 5
- 238000000576 coating method Methods 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 3
- 235000019800 disodium phosphate Nutrition 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- 238000005507 spraying Methods 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920001688 coating polymer Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (20)
1. Oralno primjenjive farmaceutske pelete koje imaju jezgru i gastrorezistentnu ovojnicu, gdje jezgra sadrži farmaceutski učinkovitu količinu epidermalnog faktora rasta i antioksidans koji u svom sastavu ima sumpor, izabran iz skupine koja obuhvaća metionin i K2S2O7.
2. Pelete prema zahtjevu 1, gdje je molarni omjer između epidermalnog faktora rasta i antioksidansa od 1:20 do 1:60.
3. Pelete prema bilo kojem od zahtjeva 1-2, gdje jezgra dalje sadrži vezivo, alkalno sredstvo, sredstvo za podmazivanje, surfaktant ili njihove mješavine.
4. Pelete prema zahtjevu 3, gdje je vezivo hidroksipropilmetilceluloza.
5. Pelete prema zahtjevu 3, gdje je alkalno sredstvo dinatrijev fosfat.
6. Pelete prema zahtjevu 3, gdje je sredstvo za podmazivanje talk.
7. Pelete prema zahtjevu 3, gdje je surfaktant natrijev lauril sulfat.
8. Pelete prema bilo kojem od zahtjeva 1-7, gdje jezgra sadrži:
60-80% težine inertne jezgre;
0.05-1 % težine epidermalnog faktora rasta;
0.5-3% težine antioksidansa;
0.02-0.07% težine surfaktanta;
1.5-5% težine veziva;
0.02-0.07% težine alkalnog sredstva; i
2-5% težine sredstva za podmazivanje.
9. Pelete prema zahtjevu 8, gdje jezgra sadrži:
69% težine inertne jezgre;
0.10% težine epidermalnog faktora rasta;
1.3 % težine metionina;
0.05% težine natrijevog lauril sulfata;
2% težine hidroksipropilmetilceluloze;
0.05% težine dinatrijevog fosfata; i
4% težine talka.
10. Pelete prema zahtjevu 8, gdje jezgra sadrži:
69 % težine inertne jezgre;
0.10 % težine epidermalnog faktora rasta;
2 % težine K2S2O7;
0.05 % težine natrijevog lauril sulfata;
2 % težine hidroksipropilmetilceluloze;
0.05 % težine dinatrijevog fosfata; i
4 % težine talka.
11. Pelete prema bilo kojem od zahtjeva 1-10, gdje gastrorezistentna ovojnica sadrži polimer od poli(metakrilne kiseline/ metilakrilata/ metil metakrilata), trietilcitrata, natrijevog lauril sulfata, talka ili njihovih mješavina.
12. Pelete prema bilo kojem od zahtjeva 1-11, dalje sadrže međusloj ovojnice koji obuhvaća barem polimer s prilagođenim oslobađanjem.
13. Pelete prema zahtjevu 12, gdje međusloj ovojnice dalje obuhvaća sredstvo za podmazivanje.
14. Pelete prema bilo kojem od zahtjeva 12-13, gdje se polimer s prilagođenim oslobađanjem izabire iz skupine koja obuhvaća poliakrilate, polimetakrilate, etilcelulozu, hidroksipropilcelulozu, hidroksipropilmetilcelulozu i njihove mješavine.
15. Pelete prema bilo kojem od zahtjeva 12-14, gdje je polimer s prilagođenim oslobađanjem polimer od estera poli(etilakrilata/metilmetakrilata).
16. Pelete prema bilo kojem od zahtjeva 12-15, gdje je sredstvo za podmazivanje talk.
17. Postupak pripreme peleta kako su definirani prema bilo kojem od zahtjeva 1-16, a koji obuhvaća:
(a) oblaganje inertne jezgre putem sprejanja vodene suspenzije koja sadrži epidermalni faktor rasta, antioksidans i farmaceutski prikladne pomoćne tvari;
(b) sušenje aktivnog sloja nastalog u koraku (a);
(c) oblaganje jezgre iz koraka (b) sprejanjem suspenzije koja sadrži gastrorezistentni polimer za ovojnicu i farmaceutski prikladnu pomoćnu tvar; i
(d) sušenje obložene pelete nastale u koraku (c);
gdje je temperatura svakog koraka postupka do 40°C.
18. Postupak prema zahtjevu 17, za pripremu peleta kako su definirani prema bilo kojem od zahtjeva 12-16, dalje obuhvaća dodatni korak oblaganja jezgre iz koraka (b) putem sprejanja suspenzije koja sadrži polimer s prilagođenim oslobađanjem i farmaceutski prikladnu pomoćnu tvar; i sušenje nastalog sloja.
19. Farmaceutski oblik kapsule koja sadrži pelete kako su definirani prema bilo kojem od zahtjeva 1-16.
20. Farmaceutske pelete kako su definirani prema bilo kojem od zahtjeva 1-16, za uporabu u liječenju ulceroznog kolitisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382033A EP2364690A1 (en) | 2010-02-12 | 2010-02-12 | Orally administrable pharmaceutical pellet of epidermal growth factor |
| EP11702645.0A EP2533758B1 (en) | 2010-02-12 | 2011-02-10 | Orally administrable pharmaceutical pellet of epidermal growth factor |
| PCT/EP2011/051918 WO2011098499A1 (en) | 2010-02-12 | 2011-02-10 | Orally administrable pharmaceutical pellet of epidermal growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150643T1 true HRP20150643T1 (hr) | 2015-08-14 |
Family
ID=42355395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150643TT HRP20150643T1 (hr) | 2010-02-12 | 2015-06-15 | Oralno primjenjive farmaceutske pelete s epidermalnim faktorom rasta |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9205130B2 (hr) |
| EP (2) | EP2364690A1 (hr) |
| JP (1) | JP5778184B2 (hr) |
| KR (1) | KR101745750B1 (hr) |
| CN (1) | CN102753146B (hr) |
| AR (1) | AR080144A1 (hr) |
| AU (1) | AU2011214421B8 (hr) |
| BR (1) | BR112012020223B8 (hr) |
| CA (1) | CA2789055C (hr) |
| DK (1) | DK2533758T3 (hr) |
| ES (1) | ES2537704T3 (hr) |
| HR (1) | HRP20150643T1 (hr) |
| HU (1) | HUE024986T2 (hr) |
| MX (1) | MX2012009217A (hr) |
| PL (1) | PL2533758T3 (hr) |
| PT (1) | PT2533758E (hr) |
| RS (1) | RS54098B1 (hr) |
| RU (1) | RU2540503C2 (hr) |
| SI (1) | SI2533758T1 (hr) |
| SM (1) | SMT201500158B (hr) |
| WO (1) | WO2011098499A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432737B (zh) * | 2011-09-07 | 2015-02-25 | 张绍国 | 一种缓释肠溶丙烯酸树脂乳胶液及其制法 |
| EP2968529B1 (en) | 2013-03-14 | 2020-08-05 | Aimmune Therapeutics, Inc. | Manufacture of peanut formulations for oral desensitization |
| CN113966229A (zh) | 2019-05-10 | 2022-01-21 | 爱沐疗法公司 | 用于改善花生过敏患者的生活质量的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62149622A (ja) * | 1985-12-24 | 1987-07-03 | Wakunaga Pharmaceut Co Ltd | 腸機能改善剤 |
| US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
| DE3778275D1 (de) * | 1986-08-07 | 1992-05-21 | Roehm Gmbh | Verfahren zur herstellung eines redispergierbaren kunststoffpulvers. |
| JPH01246223A (ja) * | 1988-03-28 | 1989-10-02 | Hitachi Chem Co Ltd | 潰瘍治療剤 |
| US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| WO1999030671A2 (en) * | 1997-12-15 | 1999-06-24 | Ron Eyal S | Aspected particles for oral delivery |
| US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| EP2283856B1 (en) * | 2002-06-21 | 2017-09-20 | Novo Nordisk Health Care AG | Stabilised solid compositions of factor VIIa polypeptides |
| BR0314356A (pt) | 2002-09-16 | 2005-07-19 | Wyeth Corp | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas |
| DE10332160A1 (de) * | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
| JP2007513983A (ja) * | 2003-12-16 | 2007-05-31 | ユニバーシティー・テクノロジーズ・インターナショナル・インコーポレイテッド | 壊死性腸炎のための治療 |
| EP1986674A4 (en) | 2006-02-13 | 2009-11-11 | Nektar Therapeutics | PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME |
| MXPA06013015A (es) * | 2006-11-09 | 2007-02-07 | Gastronomia Molecular S A | Nuevo proceso de elaboracion y estabilidad de un producto nutritivo de amaranto. |
| CN102209554A (zh) * | 2008-09-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 用于防止蛋白质氧化降解的组合物和方法 |
-
2010
- 2010-02-12 EP EP10382033A patent/EP2364690A1/en not_active Withdrawn
-
2011
- 2011-02-07 AR ARP110100394A patent/AR080144A1/es unknown
- 2011-02-10 PL PL11702645T patent/PL2533758T3/pl unknown
- 2011-02-10 CA CA2789055A patent/CA2789055C/en not_active Expired - Fee Related
- 2011-02-10 PT PT117026450T patent/PT2533758E/pt unknown
- 2011-02-10 HU HUE11702645A patent/HUE024986T2/en unknown
- 2011-02-10 EP EP11702645.0A patent/EP2533758B1/en active Active
- 2011-02-10 AU AU2011214421A patent/AU2011214421B8/en not_active Ceased
- 2011-02-10 CN CN201180008952.2A patent/CN102753146B/zh not_active Expired - Fee Related
- 2011-02-10 RU RU2012139030/15A patent/RU2540503C2/ru active
- 2011-02-10 US US13/578,211 patent/US9205130B2/en not_active Expired - Fee Related
- 2011-02-10 ES ES11702645.0T patent/ES2537704T3/es active Active
- 2011-02-10 RS RS20150439A patent/RS54098B1/en unknown
- 2011-02-10 SI SI201130525T patent/SI2533758T1/sl unknown
- 2011-02-10 KR KR1020127023348A patent/KR101745750B1/ko active IP Right Grant
- 2011-02-10 MX MX2012009217A patent/MX2012009217A/es active IP Right Grant
- 2011-02-10 WO PCT/EP2011/051918 patent/WO2011098499A1/en active Application Filing
- 2011-02-10 JP JP2012552388A patent/JP5778184B2/ja not_active Expired - Fee Related
- 2011-02-10 BR BR112012020223A patent/BR112012020223B8/pt not_active IP Right Cessation
- 2011-02-10 DK DK11702645.0T patent/DK2533758T3/da active
-
2015
- 2015-06-15 HR HRP20150643TT patent/HRP20150643T1/hr unknown
- 2015-07-03 SM SM201500158T patent/SMT201500158B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150643T1 (hr) | Oralno primjenjive farmaceutske pelete s epidermalnim faktorom rasta | |
| HRP20120766T4 (hr) | Formulacija za isporuku lijeka u kolonu | |
| JOP20200145B1 (ar) | تركيبة عقار ذو إطلاق متأخر | |
| AU2007267159B2 (en) | Lipoic acid pellets | |
| JP2017535521A5 (hr) | ||
| BR112012008626A2 (pt) | forma farmacêutica oral sólida com liberação modificada de pelo menos um ingrediente ativo | |
| FI3236943T3 (fi) | Koostumuksia ileo-jejunaaliseen lääkkeenantoon | |
| JP2016532655A5 (hr) | ||
| TN2013000220A1 (en) | Orally disintegrating tablet | |
| JP2010270128A5 (hr) | ||
| RU2008137766A (ru) | Твердые дозированные формы | |
| RU2015110825A (ru) | Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола | |
| IT9020054A1 (hr) | ||
| JP2016535030A5 (hr) | ||
| HU231030B1 (hu) | Többszörös bevonattal ellátott gyógyszer dózisforma | |
| JP2008507483A (ja) | 安定な作用物質放出プロフィールを有するコーティングされた剤形の製造方法 | |
| HRP20240033T1 (hr) | Formulacija koja sadrži inhibitor mek | |
| PT828480E (pt) | Nova formulacao farmaceutica em micropastilhas | |
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| JP2019513800A5 (hr) | ||
| JP2007509891A5 (hr) | ||
| PH12017501363B1 (en) | Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them | |
| HRP20200891T1 (hr) | Laktoferin za liječenje upalnih bolesti crijeva (ibd) povezanih s bakterijskim napadom | |
| HRP20191072T1 (hr) | Farmaceutski pripravak s produljenim otpuštanjem trimetazidina | |
| SI2773348T1 (en) | PHARMACEUTICAL COMPOSITION OF OMEPRAZOLE |